Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA6 | P17658 | 9/20 | 1.00 |
| ▸ | KCNA3 | P22001 | 9/20 | 1.00 |
| ▸ | KCNA4 | P22459 | 9/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 3/20 | 1.00 |
| ▸ | NT5E | P21589 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | KCNA2 | P16389 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oroidin SCHEMBL13036738 | 1.00 | KCNA6 (1.00) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| SCHEMBL13074094 | 0.85 | KCNA6 (0.74) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| SCHEMBL13036733 | 0.82 | KCNA6 (1.00) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| SCHEMBL21182348 | 0.82 | KCNA6 (1.00) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| Oroidin SCHEMBL28891358 | 0.79 | KCNA6 (0.65) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| Oroidin SCHEMBL14536687 | 0.79 | KCNA6 (0.65) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| Oroidin SCHEMBL12597862 | 0.79 | KCNA6 (0.65) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| Clathrodin SCHEMBL13036737 | 0.79 | NT5E (1.00) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| Clathrodin SCHEMBL13036741 | 0.79 | NT5E (1.00) | KCNA6KCNA3KCNA4KCNA5NT5E | |
| SCHEMBL13036715 | 0.75 | KCNA6 (0.61) | KCNA6KCNA3KCNA4KCNA5NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838681-B2 | Synthesis of substituted heterocyclic compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-23 | — | — | US | disclosed |
| US-20070106077-A1 | Synthesis of substituted heterocyclic compounds | UNIVERSITE DE PARIS SUD (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106077-A1 | Synthesis of substituted heterocyclic compounds | CBR1, CORO1C, CYCS | KCNA6 3183/4885KCNA3 2480/4885KCNA4 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.